What's Happening?
A Danish nationwide study published in Human Reproduction Open found that women who used semaglutide or liraglutide (GLP-1 type drugs) for weight loss around the time of conception did not have an increased risk of preterm birth. However, a higher risk of preterm birth was
observed among women prescribed these same drugs for diabetes. The study analyzed 756,636 single-baby pregnancies, with only 529 involving a GLP-1 prescription filled in the eight weeks before or after the first day of the last menstrual period. Of these, 211 were in women with diabetes. After accounting for factors like age, BMI, smoking, and pre-existing diabetes, the link with preterm birth remained only for women prescribed the drugs for diabetes, suggesting that the underlying condition of diabetes, rather than the medication itself, may be the driving factor for earlier delivery.
Why It's Important?
This study provides crucial, albeit preliminary, reassurance for women in the U.S. who may inadvertently become pregnant while taking GLP-1 medications for weight loss. With the increasing use of these drugs among women of reproductive age, unplanned pregnancies are a growing concern. The findings suggest that accidental exposure to GLP-1s for weight management around conception might not carry the same preterm birth risks as exposure in diabetic patients. This distinction is vital for counseling patients and managing anxieties surrounding medication use during early pregnancy. However, the study does not establish the overall safety of GLP-1 drugs in pregnancy, and current medical advice still recommends discontinuing these medications before a planned pregnancy.
What's Next?
Despite these findings, current medical advice to stop GLP-1 drugs before a planned pregnancy remains unchanged. For instance, Wegovy's prescribing information advises discontinuation at least two months prior to conception. Researchers emphasize the need for larger studies that clearly differentiate between diabetes users and weight-loss users, and to gather data on other GLP-1 drugs like tirzepatide, exposure later in pregnancy, and long-term health outcomes for children. Women who discover they are pregnant while on a GLP-1 medication should promptly contact their prescriber and an obstetric provider. Diabetic women, in particular, should not stop their medication without a medical plan, as blood sugar control is critical for both maternal and fetal health. Clinicians will need to continue providing individualized counseling based on the latest evidence and patient circumstances.
Beyond the Headlines
This research opens a broader discussion about the complexities of medication use in pregnancy and the challenges of distinguishing between disease effects and drug effects. The finding that diabetes itself, rather than the GLP-1 medication, may be linked to higher preterm birth risk highlights the critical importance of managing underlying health conditions during pregnancy. It also underscores the limitations of observational studies, which can show associations but not direct causation. As GLP-1 use continues to rise, particularly among women, there will be an increasing need for robust, long-term studies to fully understand their impact on reproductive health and fetal development. This will likely influence future prescribing guidelines, patient counseling strategies, and potentially lead to more tailored approaches for women of childbearing age using these powerful medications.
